Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement - 02/11/21
, Rodolphe Anty c, d, e, Claire Carette f, Bertrand Cariou g, Laurent Castera h, i, Cyrielle Caussy j, k, Helene Fontaine l, Armand Garioud m, Pierre Gourdy n, o, Bruno Guerci p, Maeva Guillaume q, r, Niasha Michot s, Anne Minello t, Dann J Ouizeman c, Lawrence Serfaty u, Fabrice Bonnet v, Bruno Vergès w, x, Jean-Michel Petit w, xon behalf of
Abstract |
Type 2 diabetes mellitus (T2DM) is a frequent comorbidity in patients with cirrhosis that is projected to rise in prevalence due to the worldwide burden of obesity, insulin-resistance and non-alcoholic fatty liver disease. The management of T2DM in patients with cirrhosis is complex given the requirement for accurate adaptation according to the level of liver function impairment, with lack of summary of the little evidence available in the literature. Here, we summarise the data available with respect to the epidemiology and the impact of T2DM in patients with cirrhosis, as well as those on the management of T2DM in these patients. We provide guidance for the diagnosis of T2DM and the monitoring of glycaemic control in patients with cirrhosis, and for the management of nutrition and pharmacological treatments in relation to the level of liver dysfunction.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Cirrhosis, Diagnosis, Epidemiology, Monitoring, Pharmacological treatment, Type 2 diabetes mellitus
Abbreviations : ADA, 2h-PG, AUC, CGM, Cmax, EASD, FPG, GLP-1 RAs, HbA1c, HCC, NAFLD, NASH, OGTT, SGLT2i, T2DM
Mappa
Vol 47 - N° 5
Articolo 101272- settembre 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
